 PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 PRNewswire -- OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec today announced it has entered into a Clinical Trial Collaboration and Supply Agreement Agreement with Merck known as MSD outside the United States and Canada to evaluate the combination of OncoSecs DNA-plasmid interleukin-12 IL-12 TAVOTM tavokinogene telseplasmid with Mercks anti-PD-1 therapy, KEYTRUDA pembrolizumab, in a global Phase 3 randomized clinical trial, KEYNOTE-C87. 